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Abstract 
Background: To determine the frequency of 
different genotypes in HCV positive cases in the 
population of Rawalpindi/ Islamabad over the 
period of five years. 
Methods: Data of total of three thousand eight 
hundred and eighteen (n=3818) HCV positive adult 
of both genders screened for genotype testing over 
the period of six years were analyzed.   
Results: Most frequent genotype identified in our 
study was genotype 3, accounting for 95.8%. The 
second most common genotype was Type 1 (2.9%). 
Other genotypes were Type 2 (0.3%)and Type 4 
(0.1%). Mixed genotype (Type 1 and 3) were detected 
in  1 %.  Genotype 5 and 6 was not detected in any 
case. No significant difference was observed among 
males and females in genotype distribution (p>0.05).  
Conclusion: Most common genotype among HCV 
patients was genotype 3, followed by genotype 1.   
Key Words: HCV,HCV genotype,Interferon 
therapy, Viral Infection 
Introduction 
Determination of an individual’s HCV genotype prior 
to antiviral therapy has become increasingly important 
for the deciding clinical management and predicting 
prognosis of HCV infection. Relative genotype 
proportions are needed to inform to healthcare 
models, which should be geographically tailored. 
Hepatitis C virus (HCV) is a globally prevalent 
pathogen and one of the major causes of mortality and 
morbidity especially in developing countries like 
Pakistan.1,2 Recent estimates revealed an increase in its 
seroprevalence over the last 10-15 years to 2.8%, 
corresponding to > 185 million infections worldwide.3 
Prevalence of HCV infections in Pakistani population 
has been estimated to be 8% and is increasing day-by-
day.4,5 HCV has been classified into 1-6 major 
genotypes on the basis of phylogenetic analysis of 
nucleotide sequences.6 HCV genotypes have different 
biological properties, clinical outcome and response to 
antiviral treatment. Study of genotyping pattern 
provides important clues about transmission and 
pathogenesis as well as contributes to the development 
of an effective preventive and curative strategy. 7 HCV 
genotypes and subtypes have variable distribution 
around the globe. Predominant genotypes in the 
United States and Europe are 1a and 1b respectively.8,9 
HCV genotype 2  is more prevalent in countries of 
West Africa  while genotype 3a is more frequently 
found in Australia and South Asia. 10,11  Moreover, 
genotypes 4, 5 and 6 are frequently found in Central 
Africa, South Africa and Asia.12 All these HCV 
genotypes show 31-34% heterogeneity in their 
nucleotide sequences and approximately 30% 
heterogeneity in their amino acid 
sequences.13Although genotype 3 is reported as most 
prevalent form in Pakistan, yet, studies have shown 
regional variations in the prevalence of different 
genotypes. Other genotypes were also present in the 
patients infected with HCV, but were of lesser 
frequency. 14,15  
The goal of treatment is to eradicate HCV RNA, which 
is predicted by the achievement of a sustained 
virologic response (SVR) as defined by the absence of 
HCV RNA by polymerase chain reaction (PCR) 12 
weeks after stopping treatment. An SVR is associated 
with a 99 percent chance of being HCV RNA negative 
during long-term follow-up and strongly depend on 
HCV genotype 16. Determination of HCV genotype is 
thus essential for making decisions regarding regimen 
selection, dosing and duration of therapy 17. It has 
been reported that high SVR rates with only 24 weeks 
of carefully selected regimens were achieved among 
most patients with genotype 3 infection 18.   
HCV is becoming a growing public health concern in 
Pakistan and to our knowledge, there are few studies 
reporting genotype pattern in Rawalpindi/Islamabad 
region.   Relative genotype proportions are needed to 
inform to healthcare models, which should be 
geographically tailored.    
Patients and Methods 
It was a retrospective cross-sectional study carried out 
at Nuclear Medicine, Oncology and Radiotherapy 
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Institute (NORI), Islamabad, Pakistan. The study was 
observational in nature and all diagnosed cases of 
HCV infection referred for genotpye testing on routine 
basis were included (non-probability purposive 
sampling). Results of individual patient were duly 
informed and consent was taken for enrollment for 
analysis of consolidated results. We did not use any 
sample size calculation formula or pilot study to 
calculate the sample size. Data collected over a period 
of six years (Jan 2010 to December 2015) were 
analyzed. Study design was approved by the hospital 
ethical committee. HCV RNA was extracted and 
reverse transcribed to synthesis cDNA that was further 
subjected to nested PCR for detection of HCV viral 
RNA. The multiplex PCR genotyping for HCV was 
done only for the samples with detected HCV-RNA.  
 
Results 
A total of three thousand eight hundred and eighteen 
(n=3818) HCV positive adults of both genders were 
screened for genotype testing during the period. 
Females constituted 54.6%, and mean age was 40.4 
years (Table 1).Most frequent genotype identified in 
our study was genotype 3, accounting for 95.8% 
(n=3657) (Table 2).Mixed genotype (Type 1 and 3) 
were detected in 1 % (n=35) of cases.  Genotype 5 and 
6 was not found in any case. No significant difference 
was observed among males and females in genotype 
distribution (p>0.05) (Table 3).   
 
Table 1: Gender and Age distribution in study 
sample 
Gender Number  




Males 1732 (45.4%) 39.6 12.2 
Females 2086 (54.6%) 41.1 10.7 
Total 3818 (100%) 40.4 11.4 
 
Table 2: Frequency of genotype in study sample 
HCV Genotype Frequency Percent 
Type 1 109 2.9 
Type 2 12 0.3 
Type 3 3657 95.8 
Type 4 5 0.1 
Mixed type 1 and 3 35 0.9 
Total 3818 100.0 







Genotype Males Females 
Type 1 
59 50 109 
0.464 
(54.1%) (45.9%) (100.0%) 
Type 2 
5 7 12 
(41.7%) (58.3%) (100.0%) 
Type 3 
1650 2007 3657 
(45.1%) (54.9%) (100.0%) 
Type 4 
2 3 5 
(40.0%) (60.0%) (100.0%) 
Mixed type 
1 and 3 
16 19 35 
(45.7%) (54.3%) (100.0%) 
Total 
1732 2086 3818 
(45.4%) (54.6%) (100.0%) 
 
Discussion 
HCV is reported to exhibit high genetic diversity, 
characterized by regional variations in genotype 
prevalence. This poses a challenge to the improved 
development of vaccines and pan-genotypic 
treatments, which require the consideration of global 
trends in HCV genotype prevalence. Situation in 
Pakistan is even worse where published data is scarce 
and most data are based on relatively smaller sample 
size leaving a big question mark for the significance of 
the results published by these authors.   
It has been reported that Pakistan seems to have high 
prevalence of hepatitis C virus type 3. 19 About 10 
million Pakistani population is infected with Hepatitis 
C virus (HCV). The prevalence is even more 
pronounced among high risk population.20  In this 
study, we gathered data over the period of six years 
and a total of three thousand eight hundred and 
eighteen (n=3818) HCV positive adult of both genders 
were screened for genotype testing during this period. 
 Our results showed that Most frequent genotype 
identified in our study was genotype 3, accounting for 
95.8% (n=3657) of HCV positive cases. The second 
most common genotype was Type 1 accounting for 
2.9% (n=109) of HCV positive cases. No significant 
difference was observed among males and females in 
genotype distribution (p>0.05).  Our results are 
comparable with one of the largest sample sized study 
conducted in Pakistan. Attaullah S et al, reviewed 34 
published papers (1996-2011) related to prevalence of 
HCV genotypes/serotypes and subgenotypes in 
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Pakistan. 21 HCV genotype/s distribution from all 34 
studies was observed in 28,400 HCV infected 
individuals in the following pattern: 1,999 (7.03%) 
cases of genotype 1; 1,085 (3.81%) cases of genotype 2; 
22,429 (78.96%) cases of genotype 3; 453 (1.59%) cases 
of genotype 4; 29 (0.10%) cases of genotype 5; 37 
(0.13%) cases of genotype 6; 1,429 (5.03%) cases of 
mixed genotypes, and 939 (3.30%) cases of untypable 
genotypes. Genotype 3 occurred predominantly in all 
the provinces of Pakistan. Second more frequent 
genotype was genotype 1 in Punjab province and 
untypable genotypes in Sindh, Khyber Pakhtunkhwa 
and Balochistan provinces. The apparent differences 
from the current study (78.9% vs 95.8%) may be 
explained by the changing trends over time. They 
reported data gathered till 2011 while we gathered 
data from 2010 to 2015. The difference may also be 
attributed to the geographical difference. We 
published data exclusively of Rawalpindi/Islamabad 
region and they reviewed data of whole of the 
country. Inherent heterogeneity of data problems in 
such kinds of systematic review may also be attributed 
to the apparent differences in the results these two 
studies. However, the trends are generally similar. 
Hussain A et al, reported the frequency distribution of 
HCV genotypes in a tertiary care centre of Karachi, the 
largest metropolitan city of Pakistan, where people of 
all ethnic origins are found. 22 HCV genotyping was 
performed on a total of 457 patients who tested 
positive for presence of Hepatitis “C” viral RNA. The 
most prevalent genotype was type 3 with 392 (85.8%) 
cases, followed by type 1 with 51 (11.2%) cases. Our 
results are also comparable with  other numerous 
studies where  genotype 3 reported as remain the most 
prevalent subtype infecting people in Pakistan. 23-37   
The comparison of present data with global prevalence 
data, it is  with Messina JP et al, who in their large 
meta analysis included 1,217 studies in our analysis, 
representing 117 countries and 90% of the global 
population. 38 They found HCV genotype 1 is the most 
prevalent worldwide, comprising 83.4 million cases 
(46.2% of all HCV cases), approximately one-third of 
which are in East Asia. Genotype 3 is the next most 
prevalent globally (54.3 million, 30.1%); genotypes 2, 4, 
and 6 are responsible for a total 22.8% of all cases; 
genotype 5 comprises the remaining <1%. While 
genotypes 1 and 3 dominate in most countries 
irrespective of economic status, the largest proportions 
of genotypes 4 and 5 are in lower-income countries.  In 
another study by Petruzziello A et al, who reviewed 
HCV prevalence and genotypes distribution 
worldwide, reported HCV prevalence is estimated at 
2.5% (177.5 million of HCV infected adults), ranging 
from 2.9% in Africa and 1.3% in Americas, with a 
global viraemic rate of 67% (118.9 million of HCV 
RNA positive cases), varying from 64.4% in Asia to 
74.8% in Australasia. 39 HCV genotype 1 is the most 
prevalent worldwide (49.1%), followed by genotype 3 
(17.9%), 4 (16.8%) and 2 (11.0%). Genotypes 5 and 6 
are responsible for the remaining < 5%.  
It has been reported in several studies that genotype 3 
is associated with better treatment responses.17,18  
Treatment response depends on lot of factors other 
than genotype. We emphasize in focusing on 
preventing the infection by developing suitable 
vaccines against genotype 3 as it was found to be the 
most common type in our population is. HCV 
infection is becoming a public health issue in Pakistan 
and enormous efforts need to be done by public health 
authorities to educate the general population about the 
prevention and importance of early detection and start 
of curative therapy.  This is our general observation 
during our routine clinical practice that disease is 
generally affecting the poor masses and entails higher 
budget allocations from the government for 
prevention and control.  
 
Conclusion 
1.The most common type found in the region of 
Rawalpindi/Islamabad was genotype 3 followed by 
genotype 1 
2. Genotype 3, being the commonest, predicts good 
prognosis  
3. Centralized infectious diseases data registry system 
is needed which would pave the way towards 
effective control of the disease in Pakistan.  
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